Summit Master_rgb_png.png
Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
April 26, 2016 07:00 ET | Summit Therapeutics plc
Enrolment of Patients with DMD in the US Expected to Start 3Q 2016Utrophin Modulation Offers Differentiated Approach in DMD OXFORD, United Kingdom, April 26, 2016 (GLOBE NEWSWIRE) -- Summit...
Race to Yes Calls on FDA Advisory Committee: Carefully Consider Data and Recommend Duchenne Drug Approval Based on Data and Direct Experience of Children and Clinicians
April 22, 2016 12:49 ET | The Race to Yes
WASHINGTON, April 22, 2016 (GLOBE NEWSWIRE) -- In what is predicted to be the largest turnout in history at an FDA Advisory Committee meeting, more than 800 clinicians, researchers, patients and...
Summit Master_rgb_png.png
Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
March 30, 2016 07:00 ET | Summit Therapeutics plc
OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
March 15, 2016 07:00 ET | Summit Therapeutics plc
OXFORD, United Kingdom, March 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Fiscal 2015 Financial Results
February 29, 2016 16:02 ET | FibroGen, Inc.
SAN FRANCISCO, Feb. 29, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the year ended December...
Summit Master_rgb_png.png
Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in Duchenne Muscular Dystrophy
August 17, 2015 07:00 ET | Summit Therapeutics plc
Primary Objective Met; Plasma Absorption of SMT C1100 Observed at a Level Suitable for Further Development SMT C1100 to Progress into Phase 2 Open-label Trial Conference Call Scheduled...
CureDuchenne logo
Anaheim Ducks Captain Ryan Getzlaf to Host 2nd Annual Getzlaf Golf Shootout This Weekend to Benefit Cure Duchenne
September 05, 2012 13:09 ET | CureDuchenne
NEWPORT BEACH, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Ryan Getzlaf, captain of the Anaheim Ducks, is hosting the second annual Getzlaf Golf Shootout on September 9 to benefit CureDuchenne, a...
CureDuchenne logo
"I am a Duchenne Dad" Online Community
March 13, 2012 12:54 ET | CureDuchenne
NEWPORT BEACH, Calif.,, March 13, 2012 (GLOBE NEWSWIRE) -- Paul Miller, Cure Duchenne co-founder, announces the creation of the "I Am a Duchenne Dad" online community, a new Facebook group to connect...
CureDuchenne logo
Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne Muscular Dystrophy
February 21, 2012 13:34 ET | CureDuchenne
Newport Beach, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a nonprofit organization that raises awareness and funds multiple research and development projects to cure Duchenne muscular...
CureDuchenne logo
Cure Duchenne Launches Online Fundraising Gift Store in Time for Valentine's Day
February 08, 2012 12:22 ET | CureDuchenne
Newport Beach, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a nonprofit that raises awareness and funds research to cure Duchenne muscular dystrophy, has launched an online fundraising gift...